BOSTON, Aug 26 /PRNewswire-FirstCall/ -- China PharmaHub Corp. ("PharmaHub"), which has recently merged with World Wide Relics (OTC Bulletin Board: WRLC) which has changed its name to China PharmaHub Corp, and is in the process of obtaining approval from FINRA to trade under its new name with a new symbol, announced today that it has signed an Exclusive Distribution Agreement ("Agreement") with a world leader in precision glass technology which can be utilized to manufacture high precision radioactive glass spheres that emit alpha, beta or gamma radiation, either individually or in combination, for the treatment of malignant tumors of the liver.
Celsion Receives Fast Track Designation for ThermoDox® Development Program to Treat Primary Liver Cancer
COLUMBIA, Md., Aug. 24 /PRNewswire-FirstCall/ -- Celsion Corporation (Nasdaq: CLSN), a leading oncology drug development company, today announced that the U.S. Food and Drug Administration (FDA) has designated the HEAT Study of its investigational drug, ThermoDox®, in combination with radiofrequency ablation (RFA), as a Fast Track Development Program.
Multi-centre Phase II Trial Reports Safety and Clinical Benefits of Radioactive Microspheres in Patients with Colorectal Cancer Liver Metastases who h
ROME, August 19, 2010 /PRNewswire/ -- Radioactive yttrium-90 labelled
resin microspheres (SIR-Spheres; Sirtex Medical, Sydney, Australia) appear to
be a safe and effective treatment for patients with colorectal cancer liver
metastases who have failed available chemotherapy options, according to the
final results of a prospective clinical multi-centre phase II trial conducted
by the Italian Society of Locoregional Therapies in Oncology (SITILO) and
published in the British Journal of Cancer.[1]
The results of the 52-patient study revealed that the liver tumours
completely disappeared in one patient (2%), and 11 (22%) patients had a
partial response involving at least a 30% reduction in tumour size, which met
the pre-determine...
